UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.
ASJC Scopus subject areas
Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders". / Lazaridis, Konstantinos N.; Gores, Gregory J.; Lindor, Keith.In: Journal of Hepatology, Vol. 35, No. 1, 2001, p. 134-146.
Research output: Contribution to journal › Article